Global Conjunctivitis Drugs Market Size, Share, Forecast Report, 2020-2027

Conjunctivitis Drugs Market is expected to register 3.1% CAGR during the forecast period of 2019 to 2025 and will be valued at USD 1.18 Billion in 2025.

Conjunctivitis is commonly known as “pink eye” is an inflammation or swelling of the conjunctiva.

The prevalence of conjunctivitis or pink eye is increasing globally, fueling market growth. Conjunctivitis drugs are used for the treatment of conjunctivitis. There are various types of conjunctivitis including bacterial, allergic, viral, and chemical. Conjunctivitis affects millions of people and imposes economic and social burdens. In the US, it is estimated that acute conjunctivitis affects about 6 million people annually. The major factors influencing the growth of the market include increasing prevalence of conjunctivitis. Bacterial conjunctivitis is the second most common cause and is responsible for the majority 50–75% of the cases in children. It is found that primary care physicians are the first point of treatment for most of the conjunctivitis patients rather than eye care professionals. About 1% of the visits for primary care offices in the US are associated with conjunctivitis. Moreover, a rise in hygiene and awareness, growing expenditure on health, greater exposure to allergens and infective agents, and the contagious nature of the disease are expected to drive the growth of the market.

Furthermore, factors such as appropriate diagnosis for viral conjunctivitis and limited awareness regarding advanced technologies are hampering the growth of the global market.

Segmentation

The Global Conjunctivitis Drugs Market is segmented based on conjunctivitis type, drug class, route of administration, end users, and region.

The global market for conjunctivitis drugs, by conjunctivitis type, is segmented into bacterial, allergic, viral, and chemical. The bacterial segment is further classified into hyperacute bacterial conjunctivitis, acute bacterial conjunctivitis, and chronic bacterial conjunctivitis. The allergic segment is further classified into atopic keratoconjunctivitis, simple allergic conjunctivitis, seasonal conjunctivitis, vernal conjunctivitis, and giant papillary conjunctivitis.

Viral conjunctivitis was the largest segment of the market, as viruses cause up to 80% of all cases of acute conjunctivitis. Viral conjunctivitis is more prevalent in summer and is the most common cause of infectious conjunctivitis across the globe. Furthermore, bacterial conjunctivitis expected to be the fastest-growing segment, as about 1.8% to 5.6% of all acute conjunctivitis is caused by chlamydia. Allergic conjunctivitis affects about 40 percent of the population, but only a small number of individuals pursue medical care.

Chemical conjunctivitis accounted for the least market share. Chemical conjunctivitis represents between 11.5–22.1% of ocular trauma.

Based on drug class, the global market is segmented into antibiotics, mast cell stabilizers, steroids, and others

Based on the administration, the global market is segmented into topical, oral, intra-vitreal, and others. The topical antibiotics segment accounted for the major market share as these products are most effective in reducing the period of conjunctivitis.

Based on end user, the global market is segmented into hospitals and clinics and specialty centers.

In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The conjunctivitis drugs market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European conjunctivitis drug market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The conjunctivitis drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The conjunctivitis drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key Players

Some of the key players operating in the Global Conjunctivitis Drugs Market are Akorn Pharmaceuticals (US), Alcon/ Novartis AG (Switzerland), Allergan Plc (Ireland), Bausch & Lomb (US), Actavis Plc (US), Pfizer Inc (US), Merck & Co. Inc. (US), Lupin Limited (India), and Valeant Pharmaceuticals (Canada).

Global Conjunctivitis Drugs Market, by Conjunctivitis Type

• Bacterial
  • Hyperacute Bacterial Conjunctivitis
  • Acute Bacterial Conjunctivitis
  • Chronic Bacterial Conjunctivitis
• Allergic
  • Atopic Keratoconjunctivitis
  • Simple Allergic Conjunctivitis
  • Seasonal Conjunctivitis
  • Vernal Conjunctivitis
  • Giant Papillary Conjunctivitis
• Viral
• Chemical

Global Conjunctivitis Drugs Market, by Drug Class

• Antibiotics
• Mast Cell Stabilizers
• Steroids
• Others

Global Conjunctivitis Drugs Market, by Route of Administration

• Topical
• Oral
• Intra-Vitreal
• Others

Global Conjunctivitis Drugs Market, by End Users

• Hospitals and Clinics
• Specialty Centers
• Others